Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC102 with Cisplatin and Pemetrexed in Advanced Solid Tumors and Mesothelioma
NCT02535312Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2016
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of methoxyamine hydrochloride in solid tumor and mesothelioma (2 arms), sponsored by National Cancer Institute. Primary endpoints: Number of Participants With at Least One Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 2 years and 1 more. Started Mar 2016; status: active, not recruiting.
02
Drugs
methoxyamine hydrochloride
03
Conditions
solid tumormesothelioma
Beyond the preview
Go deeper on NCT02535312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02535312.